ANNUAL REPORT
2013-14

GenomeQuébec

solutions are in the genes

SUMMARY

2 **MESSAGE** FROM THE CHAIR OF THE BOARD

3 **MESSAGE** FROM THE PRESIDENT AND CEO

4 SCIENTIFIC **ACTIVITY REPORT**

6 TECHNOLOGY CENTRES **ACTIVITY REPORT**

8 PUBLIC AFFAIRS AND COMMUNICATIONS **ACTIVITY REPORT**

10 HUMAN RESOURCES AND LEGAL SERVICE **ACTIVITY REPORT**

11 FINANCIAL **ACTIVITY REPORT**

12 FINANCIAL **STATEMENTS**

14 **MEMBERS** OF THE BOARD OF DIRECTORS, COMMITTEES AND EMPLOYEES

16 LARGE-SCALE PROJECT **OUTCOMES**

17 **ASSESSMENT** OF COMPLETED PROJECTS

Making **Genomics** Work for Citizens and Society

MISSION

In partnership with national and international leaders in life sciences, Génome Québec contributes to strengthening the competitiveness of the genomics innovation system in order to maximize its socio-economic impact in Québec, by funding major genomic research initiatives and putting in place the tools necessary for scientific and strategic development in the field.

CORPORATE INFORMATION

For more information, please contact Louise Thibault from the Public Affairs and Communications Department at 514 398-0668 ext. 232 or by e-mail at :
lthibault@genomequebec.com

Head office Génome Québec
630 René-Lévesque Blvd West, Suite 2660
Montréal, Québec H3B 1S6
514 398-0668
fax : 514 398-0883
genomequebec.com

Auditors - KPMG LLP
600 de Maisonneuve Blvd. West, Suite 1500
Montréal, Québec H3A 0A3
kpmg.com

Legal adviser
Me Jean Brunet • Stein Monast, S.E.N.C.R.L.
70 Dalhousie Street, Suite 300
Québec, Québec G1K 4B2
steinmonast.ca

Génome Canada
150 Metcalfe Street, Suite 2100
Ottawa, Ontario K2P 1P1
genomecanada.ca

Ministère de l'Économie, de l'Innovation et des Exportations
1035 De La Chevrotière
Québec, Québec G1R 5A5
economie.gouv.qc.ca

McGill University and Génome Québec Innovation Centre
740 Docteur-Penfield Avenue
Montréal, Québec H3A 1A4
514 398-7211
fax : 514 398-1790
gqinnovationcenter.com

Génome Québec and Centre hospitalier affilié universitaire régional de Chicoutimi Biobank
305 St-Vallier Street
Chicoutimi, Québec G7H 5H6
514 398-7211
infoservices@genomequebec.com

ISBN 978-2-9811988-4-6

Legal deposit – Bibliothèque et Archives nationales du Québec, 2014
Legal deposit – Library and Archives Canada, 2014

Special thanks to our partners

Économie, Innovation et Exportations Québec

GenomeCanada

MARTIN GODBOUT

Chair of the Board

Genomics has the unique ability to play a key role at every stage of the innovation chain. It is a powerful technology able to generate innovative solutions for the major societal challenges facing the Québec of tomorrow: the shift in demographics, sustainable development and economic growth.

In recent years, genomics has made giant strides and it now constitutes a major lever of socioeconomic development.

This past year, we saw the need to adapt our vision to the realities of 2014. So, with the support of the management team, the members of our Board of Directors took part in an in-depth strategic exercise. After this exercise, we concluded that a social and economic realignment was needed to ensure that the people of Québec fully benefit from the investments made in genomics over the last fourteen years.

Our vision

Genomic applications can now be used in very concrete ways. It is clear to us that the major societal challenges facing us today play a significant role in the quality of life of Quebecers and cannot be resolved without recourse to research and innovation. In light of these observations, Génome Québec chose to promote the following vision for the next five years:

Making **Genomics** Work for Citizens and Society

We are aware, of course, that this is a tall order. This vision, however, is quite relevant especially if we consider that today we no longer map genomes simply for intellectual purpose, but rather with a view to generating positive outcomes for society. As spokesperson for the Board, I am deeply committed to making sure this vision guides our orientations and decisions in the coming years.

Génome Québec is dedicated to helping society surmount its challenges through long-term investments in large-scale research and innovation projects supported by platforms at the leading edge of technology. In other words, we are intent on putting Génome Québec to work for the benefit of citizens in the Québec of tomorrow.

Our gouvernance

To reach our objectives, we are fortunate to have the support of a multidisciplinary and cross-sector Board composed of representatives from the scientific, business, academic and public administration sectors. Our members come from a variety of backgrounds and can therefore provide counsel in multiple areas, including research, health, forestry, international outreach, finance and philanthropy to name a few. Our main financial partners – the Québec Government and Genome Canada – are also represented at the table.

Together we will work in partnership with our management team to maintain good stewardship and ensure the efficient development and deployment of genomic innovations. We will do it for the benefit of citizens and society with utmost respect for ethical and accountability principles.

In closing, I would like to officially thank our Board members for their availability and valuable advice. It is a pleasure working with you. Special thanks as well to our President and CEO, Marc LePage, who is doing remarkable work, and to the members of our management team for their dedication to the betterment of society through genomics.

MARC LEPAGE

President and CEO

The year that has just come to a close has proven extremely positive from a strategic standpoint. From a crossroads between research and its applications, we have now taken a huge step closer to the real issues facing society. This is true for all four of our major priority sectors: personalized healthcare, forestry, environment and agrifood.

Our Management Committee, together with our Board of Directors, engaged in important deliberations in order to submit to the Québec Government a comprehensive strategic plan for the next five years. Adopted by the Board in December 2013, this document will support our funding requests for the coming years.

Completion of a major strategic planning exercise

Our strategic vision embodies our intent to build closer ties with society. To make this vision a reality, we plan on using a partnership-based approach, the backbone of our new plan. For us, the term partnership means building bridges with:

- Patients, foundations, the Ministry of Health and Social Services, etc.
- Private enterprises, lumber companies, environmental groups, the Ministry of Forests, Wildlife and Parks, etc.
- Rural communities, interest groups, the Ministry of Sustainable Development, Environment and the Fight against Climate Change, etc.

Finally, we will be focusing on a new priority sector: agrifood. Agrifood is Québec's largest industrial sector, and its genomic potential has thus far remained untapped. We are committed to rectifying this situation by investing heavily in the development of this highly promising niche. Of course we will be working in concert with producers, manufacturers, farmers, consumers and the Québec Ministry of Agriculture, Food and Fisheries.

In short, our strategic plan is an ambitious one designed to make genomics work for citizens and society, while contributing to the socioeconomic development of Québec.

Clinical genomic platform in pediatrics bringing hope

Last October, we announced the launch of a new partnership with CHU Sainte-Justine to create a clinical genomic platform in pediatrics. It was a major step forward for the application of genomics to rare diseases. The new platform offers hope to patients and their families facing the uncertainty of diagnostic delays by enabling them to get clear answers thanks to DNA testing. We currently often spend significant amounts without sufficient results, both from the viewpoint of patients and the government. The new platform offers the prospects of improving quality of care without increasing costs.

Québec, a world-class leader

Québec now has the potential to make its mark in several areas of genomics: expertise, partnerships, competitiveness and services. Québec researchers too are making a name for themselves and proving to be exceptional ambassadors on the international scene.

We also performed well in terms of our technological services, owing especially to the McGill University and Génome Québec Innovation Centre, which boasted a record year with a 25% increase in sales. We are proud of having served over 900 teams, more than 15% of which were international clients.

The recognition we enjoy today is because some 14 years ago Québec had the foresight to invest in genomics in a sustained manner. And this is just the beginning of something much greater.

To our management team, thank you for your dedication, rigour, energy and contribution to society. To our Board members, thank you for your invaluable support. And thank you also to our staff: you are the reason behind our great track record!

CATALINA LÓPEZ CORREA

Vice President, Scientific Affairs

2013 was a rich year in terms of growth management, both for our scientific affairs team and for the research community. Indeed, following the excellent results obtained by Québec researchers in the Genome Canada Genomics and Personalized Health competition, we chose to focus our scientific strategy on developing and strengthening our accompaniment model for scientists.

It was imperative for our team to be able to coach both the community and our project partners using clear, relevant processes. One of the most valuable coaching tools utilized this year has been the Research Monitoring Committee.

A personalized healthcare integration strategy

To ensure the future viability of projects within the health system, Génome Québec organized a series of activities involving the research community and the key players in healthcare. These were some of the initiatives created:

1) A symposium on personalized healthcare was held in Québec City on October 1 and 2, 2013 to discuss implementation and clinical applications issues in personalized healthcare. Our team has been very proactive with institutions such as the Institut national d'excellence en santé et en services sociaux (INESSS) and the Ministry of Health and Social Services (MSSS), with a view to ensuring that personalized health projects receive real support toward becoming a reality. This working dynamic is essential for the viability of projects and for setting in place the winning conditions needed to support the implementation process.

2) A symposium on genomics and personalized preventive health was organized in February 2014. The goal was to position Québec as an important player in the field of prevention and healthy lifestyles, a promising niche for the development of genomics in the healthcare field.

3) Still with the aim of putting the results and data generated by genomics in healthcare at the service of citizens, Génome Québec and CHU Sainte-Justine announced last October the launch of the first Integrated Pediatric Clinical Genomics Centre in Canada.

Genomics and Preventive Personalized Health Symposium, February 2014

Personalized Healthcare Conference, October 2013

Launch of GAPP

In 2013, Genome Canada launched a new competition, the Genomic Applications Partnership Program (GAPP). This program funds projects that utilize genomics in the search for solutions to problems identified by users. The highly applied vision of this program was relatively new to our team, especially for the priority sectors of agrifood, forestry and the environment. In order to ensure Québec researchers are well positioned in this program, we have undertaken a major process of mapping industries and potential partners. This approach allows us to play the role of networking agent between industry, universities and the public sector.

The results of this exercise have been extremely positive and we have identified a dozen teams that have projects and potential partnerships for this program.

Our challenge: Developing the agrifood sector

Our biggest challenge this year has been to stimulate the development of the agrifood sector. We have already proceeded to identify key players in both the public and the private sectors, which has enabled us to set up a positive portrait of Québec. Note that while the agrifood sector is strong in genomics, the fact remains that genomics is still not as present in Québec as in certain other Canadian provinces. In order to address the huge development potential of agrifood, our strategy will be to develop a dynamic of productive partnerships. The transferable expertise gained through the coaching and accompaniment model of the personalized health competition will help ensure the success of Québec's researchers.

Genomics and Preventive Personalized Health Symposium, February 2014

DANIEL TESSIER

Vice President, Technology Centres

2013-2014 was remarkable in terms of the operational and financial performance of the Génome Québec technology centres. This performance allowed us to respond to the primary mission of the organization, which is to provide excellent service to the scientific community in Québec, Canada and abroad.

McGill University and Génome Québec Innovation Centre

The Innovation Centre successfully initiated the start-up and technological support of six major projects in Québec and Canada resulting from the Genome Canada and Canadian Institutes of Health Research (CIHR) Personalized Health competition launched in 2012. In addition, the number of people working at the Innovation Centre rose from 174 in 2013 to 212 in 2014, which means that the McGill University recruitment initiatives are beginning to bear fruit. This result means a significant increase in the number of internal research programs at the Innovation Centre, and will provide training for new students and postdoctoral students, thereby promoting the next generation of researchers and the number of scientific publications of the Centre.

2013-2014 was a third consecutive record year, thanks to a 26% increase in service activities and a 12% increase in the number of users. The level of user satisfaction remained steady at 93%, while the level of activity for the international scientific community has remained above 10% for the last 3 years.

With record sales of close to $15 million for 2013-2014, the Centre is a model of excellence, collaboration and infrastructure sharing in Québec and throughout Canada that can serve as a powerful lever to attract international research and cooperation mandates. Currently, 907 teams of researchers use the Centre's services.

Through standardization of operations, automation and a 25% increase in next-generation sequencing equipment in mid-year, machine down-time has been reduced by 50%; this improvement is all the more impressive given the 26% increase in the number of samples sequenced in the course of the year.

REVENUE DISTRIBUTION FOR 2013-2014

Québec	Canada (excl. Québec)	International
63 %	21 %	16 %



CARTaGENE and the Génome Québec and CHAUR Biobank

While the recruitment of 17,000 participants was slated to end in 2015, it was completed by December 2013, outperforming projections in record time. One of the main factors in the success of the recruitment was the popularity of the CARTaGENE project among the Québec public, partly stimulated by very positive media coverage.

The samples were stored in the Génome Québec and Centre hospitalier affilié universitaire régional de Chicoutimi Biobank, who in turn responded to a growing demand from researchers for access to CARTaGENE's samples.

Integrated Clinical Genomic Centre in Pediatrics

By way of further developing the service offering and promoting technological integration with clinicians and patients, Génome Québec, in collaboration with CHU Sainte-Justine, announced in October 2013 the creation of the first Integrated Clinical Genomic Centre in Pediatrics in Canada. The highly innovative centre located at CHU Sainte-Justine has been designed to come up with new solutions in response to the diagnostic challenges posed by children with genetic diseases.


ICI RADIO-CANADA .ca

Cartagène à la recherche de volontaires


LE DEVOIR

Libre de penser

Un partenariat pour les maladies génétiques


TVA NOUVELLES

Membre du Groupe TVA | QUEBECOR MEDIA

CHU Sainte-Justine

Détecter une maladie génétique plus rapidement

Première publication 21 octobre 2013 à 20h09

MARIE-KYM BRISSON

Vice President, Public Affairs and Communications

Genomics is destined to play an increasingly decisive role, both in improving services to citizens and in economic development. Considering its growing impact in various sectors, it is important that the different audiences have all the information they need to guide their deliberation and decision-making process. Consequently, we increased our efforts to raise public awareness of the value and potential of genomics and to promote the dissemination of objective, credible and accessible information.

Genomics at the heart of societal issues

During the past year, a significant portion of our activities has been developed with a view to ensuring that we are included on the government's list of priorities. We have maintained the momentum established in the previous year and have capitalized significantly on the results obtained by Québec researchers in the Genome Canada Personalized Health competition. In addition, we have seized numerous opportunities to ensure that genomics occupies a central place in various consultations and conferences, including the Assises nationales de la recherche, the Rendez-vous national de la forêt québécoise, and the Strategic Forum on health of the Montreal's Board of Trade. We have multiplied opportunities for meetings and public representations in every activity sector targeted by Génome Québec: health, forestry, and the environment. We have also initiated major breakthroughs in the agrifood sector.

A healthy lifestyle : it's in our genes!

Inspired by our commitment to genomics at the service of citizens and society, we have formed a partnership with the Grand Défi Pierre Lavoie (GDPL) making Génome Québec the official scientific partner for this 1,000 km event. This initiative has provided us access to a credible mass communication vehicle whose mission is aligned with our own. In addition, on February 13 and 14, Génome Québec, in collaboration with the GDPL, organized the first International Symposium on Genomics and Personalized Preventive Health. This was a landmark event that brought together over 140 participants from the research, public health, philanthropic and government domains. The partnership will continue in 2014-2015.

Le Quotidien, 13 février 2014, page 23

Pierre Lavoie avec des sommités mondiales

STÉPHANE BÉGIN
sbegin@lequotidien.com

L'événement regroupera le Dr Frank Hu (professeur de nutrition et d'épidémiologie tium international, axé sur la prévention et les saines habi-

Pierre Lavoie, Réjean Hébert, Marc LePage
Symposium, February 2014

Génome Québec Team members
Grand défi Pierre Lavoie

A well-tested communications strategy

Over the past two years, we have set in place an effective structure that permits us to highlight and promote the projects and technology platforms funded by Génome Québec. Our communication platform is now operating optimally in the areas of government, media and public relations, web-based platforms (website, social media, storytelling, etc.) and production tools (video, advertising, etc.).

We intend to build on our achievements by reaching out to new audiences while maintaining our current audience and meeting the objectives of the 2014-2019 Strategic Plan.

61.84 % *website visits increase*

2,317 *subscribers*

503 *subscribers*

583 *subscribers*

International

On the international scene, we were able to profit from our presence at BIO2013 in Chicago by promoting the life sciences sector on an international panel devoted to integrating technology within the health system, an event that was attended by more than 60 people.

Looking ahead

We begin 2014-2015 with the arrival of a new government. Armed with the new public affairs and communications plan that was adopted in December 2013 by the Board of Directors, we will ensure that genomics remains at the heart of Québec's strategic priorities in the years to come.

ÈVE-STÉPHANIE SAUVÉ

Director, Human Resources and Legal Service

Génome Québec is currently going through a growth management phase with regard to human resource development. In this context, senior management has decided to place special emphasis on its human capital: more than ever, the organization's competitive positioning depends on the quality and excellence of its personnel, thus conferring a strategic role to the human resources function. One notable result of this new focus was the hiring, in December 2013, of an experienced specialist in this domain, Ève-Stéphanie Sauvé, the new Director of Human Resources and Legal Service.

Implementation of an organizational development plan

Among the priorities in 2013-2014 was the implementation of an organizational human resource development plan. This involved a review of the organization's policies and the social benefits affecting employees in order to ensure that they have competitive working conditions adapted to the reality of the job market. This exercise in personnel development was accompanied by the introduction of an employee recognition plan that will provide Génome Québec with the means to emphasize the positive contribution of employees and motivate them to continue their development within the organization.

Development of transversal competencies

One of the mandates of the human resources department is to develop our employees' cross-curricular skills and to provide more in-house training and development. Our medium-term objective is to develop leadership and mobilize all our human resources with a view to promoting employee retention at Génome Québec and to make them potential ambassadors of genomic research.

The challenges of the Legal Service

As regards to research project funding, one of the organization's mandates is the development of partnership agreements that are accessible and competitive for everyone involved. More specifically, it is an exercise aimed at simplifying legal terminology while demonstrating flexibility, listening and creativity, in order to conclude agreements that meet the needs of all parties involved.

A model of governance

Génome Québec wants to ensure the effectiveness of its governance and risk management mechanisms in order to maintain its role as a model of integrity in public fund management. It is vital for an organization that manages public funds to audit and ensure constant monitoring of these mechanisms, which this year led to the implementation of a strategy that gives special emphasis to an ongoing analysis of its environment and business and research and development issues.

2013 Employees gathering

CLAUDE LAMARRE

Vice President, Finance

Génome Québec receives most of its financial support from Genome Canada and the Québec Government for the funding of research projects and the operation of its technology centres.

As at March 31, 2014, our research portfolio included 44 genomic projects, and two technology centres are currently in operation. Génome Québec invested $48.7 million during the 2013-2014 fiscal year. This amount, combined with the $11.9 million invested by other partners, brings our overall injection of funds to $60.6 million, an increase of 15%.

Business volume generated by research projects during the fiscal year amounted to $39.5 million. This year, Génome Québec managed projects under eight competitions, the largest being Genomics and Personalized Health, PRAGE (a large-scale applied research project competition) and ABC (Applied Genomics Research in Bioproducts or Crops). The budget for projects still underway totals $200 million. In addition, this year, Génome Québec was mandated by the Québec government to manage a competition entitled "Fonds de partenariat pour un Québec innovant et en santé." The projects in this competition have been awarded a preliminary budget of $250 million, including the partners contribution, and will begin in the coming year.

For the year ended March 31, 2014, sales from our technology centres totalled $15.3 million, up 26% compared to last year. The technology centres posted an excess of revenues over expenses of $0.8 million. As at March 31, 2014, $2.3 million was earmarked for the development of the Innovation Centre's scientific strategic plan.

General and administrative expenses, communications and outreach costs and committee expenses totalled $3.2 million this year, an increase of $100,000 compared to last year. These expenses represent 5.3% of total investments versus 5.9% last year. Investment income reached $596,000, for a return of 2.2%.

During the fiscal year, the excess of revenues over expenses totalled $0.2 million. Unrestricted net assets rose by $597,000, and $650,000 was attributed to activities, for an amount of $3.2 million as at March 31, 2014. Net assets totalling $500,000 remain in the contingency and technological development funds, and $532,000 has been set aside for activities related to the commercialization of research findings.

Finally, Génome Québec has respected the terms and conditions in compliance with the contractual agreements it has signed with its major financial partners.



GÉNOME QUÉBEC AND INVESTMENT ACTIVITIES ($M)

- **39.5** Major projects
- **17.3** Technology centres
- **3.2** Administration
- **0.6** Investment income and others

60.6 TOTAL 2013-2014

GÉNOME QUÉBEC AND PARTNERS

- Genome Canada
- MEIE
- Other partners



Marc LePage
President and CEO
Génome Québec

Claude Lamarre
Vice President, Finance
Génome Québec

FINANCIAL STATEMENTS / STATEMENTS OF FINANCIAL POSITION March 31, 2014, with comparative information for 2013

The Statements of Financial Position as at March 31, 2014 and 2013 and the Statement of Operations for the years ended March 31, 2014 and 2013 that follow are provided as illustrative summaries only and are not intended to replace the full financial statements of Génome Québec. These full financial statements, available in French only, were audited and reported on June 17, 2014 by KPMG LLP, Chartered Professional Accountants.

	MARCH 31, 2014	MARCH 31, 2013
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	$ 3,702,844	$ 4,572,079
Short-term investments	16,136,129	17,414,409
Accounts receivable and work in progress	2,380,689	2,111,289
Advances to genomic research projects	5,278,782	1,416,999
Inventories	1,287,646	765,660
Prepaid expenses	314,985	294,068
	29,101,075	26,574,504
Long-term investments	5,446,577	18,401,474
Capital assets	568,006	502,464
	$ 35,115,658	$ 45,478,442
LIABILITIES AND NET ASSETS		
CURRENT LIABILITIES		
Accounts payable and accrued liabilities	$ 4,586,213	$ 2,995,490
Deferred revenues	101,765	143,974
Obligations related to an agreement	920,000	1,280,000
	5,607,978	4,419,464
Obligations related to an agreement	1,339,512	1,297,501
DEFERRED CONTRIBUTIONS		
Future expenses	23,383,770	35,234,538
Capital assets	429,210	347,416
	23,812,980	35,581,954
	30,760,470	41,298,919
NET ASSETS:		
Unrestricted	3,184,860	3,237,660
Restricted - Invested in capital assets	138,796	155,048
Restricted - Technology investment and contingency fund	500,000	500,000
Restricted - Research Projects	531,532	286,815
	4,355,188	4,179,523
	$ 35,115,658	$ 45,478,442

FINANCIAL STATEMENTS / STATEMENTS OF OPERATIONS Years ended March 31, 2014 and 2013

	2014	2013
REVENUES		
Amortization of deferred contributions related to expenses	$ 36,136,816	$ 27,871,962
Amortization of deferred contributions related to capital assets	214,489	282,951
Investment income	595,890	953,018
Revenues from technology centres	15,285,216	12,115,820
Other revenues	102,288	160,536
	52,334,699	41,384,287
EXPENSES		
Genomic research projects	27,443,262	20,264,698
Research projects, Innovative, Healthy Québec	165,605	–
Technology centres operational costs	20,458,242	15,790,975
Projects - Technology investment and contingency fund	664,465	732,238
General and administrative	2,638,481	2,631,400
General and administrative, Innovative, Healthy Québec	27,776	–
Communications and public outreach	369,486	381,582
Committees	91,553	28,219
Strategic initiatives	–	225,000
Gain on capital assets disposal	(69,478)	–
Depreciation of capital assets	214,489	282,951
Depreciation of restricted capital assets	113,142	134,747
	52,117,023	40,471,810
Excess of revenues over expenses	$ 217,676	$ 912,477

MEMBERS OF THE BOARD OF DIRECTORS, COMMITTEES AND EMPLOYEES

BOARD OF DIRECTORS

Chair of the Board
Martin Godbout, PhD

Vice Chairman of the Board
Daniel Bouthillier, PhD, MBA
Chief Executive Officer, Québec Network for Personalized Health Care (QNPHC)

Secretary Treasurer of the Board
Jean Brunet, Attorney
Managing Partner, Stein Monast L.L.P.

BOARD MEMBERS

Christiane Ayotte, PhD
Head of the Doping Control Laboratory
INRS – Institute Armand-Frappier Research Centre

Hélène Desmarais, C.M., LL.D.
CEO and Chair of the Board of Administration
Centre d'entreprises et d'innovation de Montréal

Thomas J. Hudson, MD
President and Scientific Director
Ontario Institute for Cancer Research

Marc LePage
President and CEO
Génome Québec

Marie-Lucie Morin

Egidio Nascimento, CA
Chief Financial Officer, VBI Vaccines

Rémi Quirion, O.C., PhD, FRSC, CQ
Chief Scientist of Québec, Fonds de recherche du Québec (FRQ)

Jacques Simoneau, PhD
President and CEO, Univalor

Paule Têtu, F. Eng., MSc
Associate to the Vice President Reasearch and Innovation, Director - Bureau for Internationalization and Partnership in Research (BIPER), Université Laval

OBSERVERS

Jean Belzile
Assistant Deputy Minister
Ministère de l'Économie, de l'Innovation et des Exportations

Pierre Meulien, PhD
President and CEO
Genome Canada

GOVERNANCE COMMITTEE

Committee Chair
Martin Godbout, PhD

Committee Secretary
Jean Brunet, Attorney
Managing Partner, Stein Monast L.L.P.

Daniel Bouthillier, PhD, MBA
Chief Executive Officer, QNPHC

Marc LePage
President and CEO
Génome Québec

Jacques Simoneau, PhD
President and CEO, Univalor

NOMINATION COMMITTEE

Committee Chair
Martin Godbout, PhD

Committee Secretary
Jean Brunet, Attorney
Managing Partner, Stein Monast L.L.P.

Christiane Ayotte, PhD
Head of the Doping Control Laboratory
INRS – Institute Armand-Frappier Research Centre

Marc LePage
President and CEO
Génome Québec

Paule Têtu, F. Eng., MSc
Associate to the Vice President Reasearch and Innovation, Director - Bureau for Internationalization and Partnership in Research (BIPER), Université Laval

FINANCE COMMITTEE

Committee Chair
Egidio Nascimento, CA
Chief Financial Officer, VBI Vaccines

Daniel Bouthillier, PhD, MBA
Chief Executive Officer, QNPHC

Jacques Simoneau, PhD
President and CEO, Univalor

HUMAN RESOURCES COMMITTEE

Committee Chair
Martin Godbout, PhD

Committee Secretary
Jean Brunet, Attorney
Managing Partner, Stein Monast L.L.P.

Marc LePage
President and CEO
Génome Québec

Rémi Quirion, O.C., PhD, FRSC, CQ
Chief Scientist of Québec, FRQ

Paule Têtu, F. Eng., MSc
Associate to the Vice President Reasearch and Innovation, Director - Bureau for Internationalization and Partnership in Research (BIPER), Université Laval

EXECUTIVE COMMITTEE

Committee Chair
Martin Godbout, PhD

Committee Secretary
Jean Brunet, Attorney
Managing Partner, Stein Monast L.L.P.

Daniel Bouthillier, PhD, MBA
Chief Executive Officer, QNPHC

Marc LePage
President and CEO
Génome Québec

Paule Têtu, F. Eng., MSc
Associate to the Vice President Reasearch and Innovation, Director - Bureau for Internationalization and Partnership in Research (BIPER), Université Laval

MANAGEMENT COMMITTEE

Marc LePage
President and CEO
Génome Québec

Marie-Kym Brisson
Vice President, Public Affairs and Communications

Claude Lamarre
Vice President, Finance

Catalina López Correa
Vice President, Scientific Affairs

Ève-Stéphanie Sauvé
Director, Human Resources and Legal Service

Daniel Tessier
Vice President, Technology Centres

STRATEGIC AND SCIENTIFIC ADVISORY BOARD (SSAB)

Committee Chair
Louise Proulx, PhD
Therillia inc., Canada

Jo Bury, PhD, MBA
VIB (Flanders Institute for Biotechnology), Belgium

Chuck Hasel, PhD, MBA
Hasel Consulting, United States

Antoine Kremer, PhD
French National Institute for Agricultural Research, France

Matthew Mailman, PhD
Janssen Research & Development, Johnson & Johnson, United States

Mark McCarthy, PhD
Wellcome Trust, United Kingdom

Teri Manolio, MD, PhD
National Human Genome Research Institute, United States

ADMINISTRATIVE CENTRE

Micheline Ayoub
Line Benguerel
Diane Bouchard
Marie-Kym Brisson
Christine Cellier
Cristina Ciurli
Hélène Fournier
Marie Céline Garand
Nathaly Hébert
Nicolas Hoffmann
Éva Kammer
Danielle Kemmer
Claude Lamarre
Ngoc Quynh Dao Le
Fabienne Lefebvre
Marc LePage
Darie Lessard
Ginette Levasseur
Catalina López Correa
Christine Martens
Ève-Stéphanie Sauvé
Louise Thibault
Vincent Trudel
Tu Linh Van

TECHNOLOGY CENTRES

Vicky Arsenault
Steve Arsenault
François-Marie Bacot
Yolande Bastien
Alexandre Belisle
Carolina Bocanegra
Julie Boudreau
Mathieu Bourgey
Guillaume Bourque
Geneviève Bourret
Sébastien Brunet
François Cantin
Valérie Catudal
Patrice Charbonneau Larose
Catherine Côté
Geneviève Dancausse
Philippe Daoust
Haig Djambazian
Geneviève DonPierre
Nathalie Émond
Joëlle Fontaine
Rosalie Fréchette
Geneviève Geneau
Philippe Gingras Gélinas
Daniel Guertin
Isabelle Guillet
Alexandru Guja
Nathalie Hamel
Louis Dumond Joseph
François Korbuly
Audrey Anne Kustec
Sylvie LaBoissière
Marc-André Labonté
François Lefebvre
Pierre Lepage
Louis Létourneau
Gary Leveque
Pascale Marquis
François Massé
Aurélie Masurel
Terrance McQuilkin
Marc Michaud
Jana Mickova
Alexandre Montpetit
Thuong Ngo
Frédérick Robidoux
Sharen Sophie Roland
Jonathan Roux
Johanna Sandoval
Élyane Simard
Janick St-Cyr
Alfredo Staffa
Daniel Tessier
Belisle Tir
Thay Leng Tony Tir
Julien Tremblay
Annie Verville
Daniel Vincent
Hoai-Thu Vo
Patrick Willett
Hao Fan Yam
Chung-Yan Yuen
Corine Zotti

FONDS DE PARTENARIAT POUR UN QUÉBEC INNOVANT ET EN SANTÉ

Marie-Paule Choquette
Stéphanie Lord-Fontaine
Joe Guillaume Pelletier
Julie Vallée

LARGE SCALE PROJECTS OUTCOMES

	Number of persons employed in the 4th Quarter 2013-2014	Number of scientists trained in the 4th Quarter 2013-2014	Number of publications accepted or submitted	Number of conferences as speaker	Number of declaration of invention or patents	Project starting date
ABC COMPETITION						
Thomas Bureau - McGill · VEGI (crop improvement)	13	6	6	1	1	october 2009
Adrian Tsang - Concordia · Genozymes (Bioproducts and Bioprocesses Development)	61.9	5	5	5	3	october 2009
Peter Facchini -UAlberta / Vincent Martin-Concordia · Phytometasyn (Synthetic Biosystems for the Production of High Value Plant Metabolite	5.7	0	9	20	9	october 2009
Richard Gold - McGill · Valgen (Value Addition Through Genomics)	14.8	5.5	1	6	0	october 2009
TOTAL	**95.4**	**16.5**	**21**	**32**	**13**	
2010 LARGE-SCALE APPLIED RESEARCH PROJECT COMPETITION						
John MacKay - ULaval / Jörg Bohlman-UBC · SMarTForest (Sustainable Forestry)	44.1	11	12	20	1	july 2011
B. Franz Lang / Mohamed Hijri - UdeM · GenoRem (Decontaminating Soils)	18	29	30	50	0	july 2011
TOTAL	**62.1**	**40**	**42**	**70**	**1**	
ENTREPRENEURSHIP EDUCATION IN GENOMICS (EEG) PROGRAM						
Denis J. Garand - ULaval · BEST in Genomics! (Optimize the Transfer of Knowledge)	5.3	1	0	14	0	october 2011
TOTAL	**5.3**	**1**	**0**	**14**	**0**	
GQ HEALTH COMPETITION						
Gregor Andelfinger - CHU Ste-Justine · Congenital Heart Disease	2.1	0	0	8	1	october 2010
Guy A. Rouleau - CHUM · Bipolar Disorder	0	0	6	7	0	october 2010
Guy Sauvageau - IRIC · Acute Myeloid Leukemia	0	0	3	2	4	october 2010
John H. White - McGill · Tuberculosis	12.5	4	4	20	0	october 2010
Ken Dewar - McGill · Digestive problems	completed	completed	0	6	0	october 2010
Mark Basik - Lady Davis Institute · Breast Cancer	8.1	1	3	6	0	october 2010
Michael Hallet - McGill · Breast Cancer	4	0.7	1	2	0	october 2010
Alain Moreau - CHU Ste-Justine · Diagnostic Tool for Pediatric Scoliosis	11.6	4	0	0	0	october 2010
Michel G. Bergeron - ULaval · Rapid Diagnostic Tests	completed	completed	0	0	0	october 2010
Maryam Tabrizian - McGill · Portative Biosensors	7.3	3.5	0	0	0	october 2010
Paul Goodyer - CUSM · Cell therapy of cystinosis	completed	completed	0	4	0	october 2010
Pavel Hamet - CHUM · Type 2 Diabetes	completed	completed	3	2	0	october 2010
Gordon Shore / Michel L. Tremblay - McGill · Cancer Therapy	7.4	1	1	1	0	october 2010
TOTAL	**53**	**14.2**	**21**	**58**	**5**	
QUÉBEC VERT COMPETITION						
François Belzile - ULaval · GreenSNPs (Environmental Genomics)	completed	completed	0	1	0	january 2012
Connie Lovejoy - ULaval · CATG (Genomics for the Arctic Environment)	completed	completed	0	1	0	january 2012
Vincent Martin - Concordia · PAYGE (Reducing Fossil Fuels Dependency)	completed	completed	0	0	0	january 2012
TOTAL	**0**	**0**	**0**	**2**	**0**	
2012 LARGE-SCALE APPLIED RESEARCH PROJECT COMPETITION • PERSONALIZED HEALTH						
Claude Perreault - HMR · Immunotherapy (Cancer)	18.5	2	1	0	1	april 2013
Patrick Cossette - CHUM · Epilepsy	10.8	2	1	0	0	april 2013
Guy Sauvageau - UdeM · Leucegene GC (Acute myeloid leukemia)	25.7	1	2	5	2	april 2013
Francois Rousseau - ULaval · PEGASUS (Prenatal aneuploidy screening using maternal blood)	21.1	6	1	7	0	april 2013
Jacques Simard - ULaval · Breast cancer (Prevention and early detection)	16.2	4	8	21	0	april 2013
John Rioux - ICM · iGenomed (Inflammatory bowel diseases)	16.6	0	0	1	0	april 2013
Jean-Claude Tardif - ICM · Cardiovascular diseases (Targeted therapeutics)	19.8	0	1	2	0	april 2013
Nada Jabado - Research Institute of the MUHC (Pediatric brain cancer)	12.7	6	3	5	0	april 2013
Sin - UBC / MacNamara, Bourbeau - McGill / Awadalla - UdeM Maltais - ULaval · COPD (disease management)	0.1	0	0	0	0	april 2013
Harrigan - UBC / Charest, Tremblay - INSPQ / Roger - UdeM / Wainberg - McGill · AIDS (response to therapies)	0.5	0	0	0	0	april 2013
McCabe - Ualberta / Gold, Kimmelman - McGill · PACE-'Omics (GE3LS, personalized medicine adoption)	5.4	2	5	5	0	april 2013
Boycott - UOttawa / Bernard, Brais, Knoppers, Majewski - UMcGillz Michaud, Samuels - UdeM · CARE for RARE (rare genetic diseases in Canada)	1.9	0	0	5	0	april 2013
TOTAL	**149.3**	**21**	**17**	**41**	**3**	
2012 BIOINFORMATICS AND AND COMPUTATIONAL BIOLOGY COMPETITION						
Jérome Waldispuhl - McGill · Science games in genomics	3	5	n/a	n/a	n/a	july 2013
Mathieu Blanchette - McGill · PIATEA	1.8	1	n/a	n/a	n/a	july 2013
Anne-Claude Gingras - Samuel Lunenfeld Research Institute / Mike Tyers - UdeM ProHits Next Generation	2	0	1	12	0	july 2013
TOTAL	**6.8**	**6**	**1**	**12**	**0**	
RECRUITEMENT COMPETITIONS						
DIRECTOR CARTaGENE						
Philip Awadalla - CHU Ste-Justine · CARTaGENE	2.5	4	13	11	0	january 2010
HUMAN HEALTH						
Mike Tyers - UdeM · Biological networks in human health	27.3	2	11	4	0	april 2011
Mark Lathrop - McGill · Medical Genomics	11	2	46	4	0	april 2011
TOTAL	**40.8**	**8**	**70**	**19**	**0**	
COMPETITION TOTAL (PROJECTS IN PROGESS)	**412.7**	**106.7**	**172**	**248**	**22**	

ASSESSMENT OF COMPLETED PROJECTS

	Number of persons employed in year-person	Number of scientists trained in year-person	Number of publications accepted or submitted	Number of conferences as speaker	Number of declaration of inventions or patents	Project duration
GQ PILOT PROJECTS COMPETITION						
Jamie Engert - CUSM · Heart Disease	3	0	0	0	0	2 years
Julie St-Pierre - McGill · Breast Cancer	3	2	1	1	0	2 years
Pierre Drapeau / Edor Kabashi - UdM · New Therapeutic Approaches	3	2	3	12	1	2 years
RRoger C. Levesque - ULaval · Budwork EcoGenomic	3.4	1	3	15	0	2 years
Sarah Kimmins - MdGill · Infertility	4.3	2	2	9	0	2 years
Zoha Kibar - CHU Ste-Justine · Neural Tube Defects	0.8	1	0	0	0	2 years
COMPETITIONS I & II, HEALTH						
Michel G. Bergeron - CHUQ · Theranostic Technologies (Diagnostic Tests to identify microbes causing infections)	118	25	25	58	11	3.25 years
Deming Xu - Private · Chemogenomics (New Therapeutic Treatments for Life-Threatening Fungal Infections)	32	2	8	4	1	3 years
Thomas J. Hudson - McGill · ARCTIC (Colorectal Cancer)	42	6	19	15	9	3.25 years
Franz Lang - UdM · Protist EST (Evolution of Eukaryotic cells' and Corresponding Genes)	49	21	20	18	0	3.5 years
Bussey/Michnick - McGill · Model Organisms (Genetic Interaction in Eukaryotic cells)	20	4	18	55	0	4 years
John J.M. Bergeron - McGill · Protéomique (Function and Structure of Genes and Proteins)	174	67	42	125	7	4 years
Fernand Labrie - ULaval · Atlas (Profiles of Steroid Action)	347	120	49	29	2	5 years
Bartha Maria Knoppers - McGill · GE3LS (Genomics and Society)	38	20	83	153	0	4 years
Fathey Sarhan - UQAM (Abiotic Stress Québec (Improve Agricultural Productivity)	82	28	11	17	0	4 years
Thomas J. Hudson - McGill · Regulatory Genetics (Identification of Regulatory Polymorphisms in the Human Genome)	117	27	16	51	6	4 years
Rafick-Pierre Sékaly - UdeM · S2K (Immune Response)	194	79	17	150	6	4 years
Mario Fillion - McGill · IGWH (Women's Health)	36	5	1	10	4	3 years
Sherif Abou Elela - USherbrooke · MoNa (genome wide analysis of gene function)	51	8	6	9	2	3 years
Adrian Tsang - Concordia · Enzymes fongiques (Environmental Remediation)	167	69	16	22	8	3 years
Benoît Coulombe - UdeM · Regulatory Networks (Decoding Genetic Information)	189	63	15	111	0	3.5 years
John MacKay - ULaval · Arborea I (Health of Trees)	98	31	23	63	2	3.5 years
Thomas J. Hudson - McGill · HapMap (Genetic Research)	34	2	14	87	1	3 years
Emil Skamene - McGill · Congenic Mice (Dissect Complex Traits Relevant to Human Health)	60	13	2	11	3	4.25 years
Guy Rouleau - UdeM · Ionic Channels (Hereditary Neurological Disorder)	40	5	0	16	3	4.25 years
Terry Roemer - Private · Candida albicans (Antifungal Drug Discovery)	51	0	2	3	3	3 years
Barry Posner / Rob Sladek - McGill · Type 2 Diabetes	5	0	25	35	6	5.5 years
Bartha Maria Knoppers - McGill · GPH (Genomics and Public Health)	5	4	22	47	0	january 2006
COMPETITION III, INTERNATIONAL CONSORTIUM INITIATIVE, PRIVAC, TECHNOLOGY DEVELOPMENT COMPETITION						
Sherif Abou Elela - USherbrooke · FAESI (Alternative Splicing)	101.5	10.8	11	28	3	5.25 years
Ken Dewar - McGill · Vervet Monkey (Neuro-development and Neurological Degradation)	18.3	2	3	4	0	4.75 years
Tomi M. Pastinen - McGill · GRID (Gene Regulators)	213	51.5	84	42	2	4.5 years
Guy A. Rouleau - UdeM · S2D (Brain Diseases)	86	12	14	41	1	5 years
Jean-Claude Tardif - ICM · Pharmacogenomics (Cardiovascular Disease)	346	41	15	87	0	4 years
John MacKay - ULaval · Arborea II (Improve Productivity of Forests Products)	186	66.6	49	95	0	5 years
Bartha Maria Knoppers / Thomas J. Hudson - McGill · P3G / CaG (Populations Genomics)	33.5	24	35	54	0	3 years
Daniel Lamarre / Sylvain Meloche - IRIC · RNA Platform (New Targeted Therapies for Cancer)	16.8	0	0	3	0	2 years
Rafick-Pierre Sékaly - UdeM · NIML Platform (Vaccines and Immune Therapeutics)	18	3	4	5	2	2 years
Michel G. Bergeron - CHUQ · GPOCT (Infectiology)	45	2	9	18	1	2.25 years
Michael Phillips / Jean-Claude Tardif - ICM · Via-PGX (Cardiovascular Pharmacogenomics)	17.5	3.6	4	44	0	2.5 years
Maryam Tabrizian - McGill · DevTab (Biomarkers Discovery and Validation)	35.3	15.2	34	13	0	2 years
Rafick-Pierre Sékaly / Ryan Brinkman - UdeM-BCCA · DevSek (Immune System)	6	1	2	4	0	2 years
TOTAL COMPLETED PROJECTS	**3.089**	**840**	**707**	**1.564**	**84**	

GenomeQuébec

@GenomeQuebec

@GenomeQC

630 René-Lévesque Blvd West, Suite 2660
Montréal (Québec) H3B 1S6

genomequebec.com